Premium
The use of frailty assessments in treating older adults with aggressive lymphomas
Author(s) -
Cordoba Raul,
Luminari Stefano,
Eyre Toby A.
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17384
Subject(s) - medicine , lymphoma , epidemiology , hodgkin lymphoma , pediatrics
Summary Non‐Hodgkin lymphomas (NHL) are most commonly diagnosed among people aged 65–74 years, with a median age at diagnosis of 67 years. The percentage of NHL‐related deaths is highest among people aged 75–84 years, with a median age at death of 76 years from cases between 2014 and 2018. In light of these recent data, attending physicians of patients with NHL will recognize that the majority of their patients will be of advanced age, with many suffering from a spectrum of frailties. The excess rate of death among older adults with NHL may be related to a range of different factors such as more challenging biologic features, undertreatment received due to a patient’s chronology and treatment‐related toxicity. The aim of this review is to provide an updated overview of the knowledge generated over recent years regarding epidemiology, prognosis and treatment options in older adults with lymphoma, focusing on Diffuse Large B‐cell Lymphoma (DLBCL) where the most robust evidence base is available.